February 2020 Vol 13, No 1

Corporate Culture of Health: Elusive and Expensive

David B. Nash, MD, MBA

Association Between Formulary Coverage and Use of Abuse-Deterrent Prescription Opioids, Risk for Abuse or Overdose, and Associated Healthcare Resource Utilization

Allison Petrilla, MPH; Elizabeth Marrett, MPH; Xian Shen, PhD, MS, BS; Winghan Jacqueline Kwong, PharmD, PhD; Edmund Pezalla, MD, MPH

Stakeholder Perspective

Abuse-Deterrent Formulations of Prescription Opioids: A Missed Opportunity to Address the Current Opioid Crisis?

Atheer A. Kaddis, PharmD

Clinical, Original Research

Medication Use Before and After Hospitalization for Chronic Obstructive Pulmonary Disease in a Cohort of Elderly Patients with a Medicare Advantage Plan

Qingqing Xu, MS; Sarah S. Laxa, PharmD; Omar Serna, PharmD, BCACP; Sujit S. Sansgiry, MS, PhD

Stakeholder Perspective

Improving Medication Use for Chronic Diseases by Reducing Costs, Increasing Patient Adherence

F. Randy Vogenberg, PhD, FASHP

Results 1 - 3 of 3

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

AHDB Print Edition

AHDB Weekly e‑Newsletter

I have reviewed and consent to the terms of AHDB's Privacy Policy, and AHDB has my permission to retain my information in its database, and to forward pertinent communications to me.